Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series
Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concent...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-08, Vol.16 (8), p.e0255983-e0255983 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0255983 |
|---|---|
| container_issue | 8 |
| container_start_page | e0255983 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Schöler, David Castoldi, Mirco Jördens, Markus S Schulze-Hagen, Max Kuhl, Christiane Keitel, Verena Luedde, Tom Roderburg, Christoph Loosen, Sven H |
| description | Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concentration and sizes of extracellular vesicles (EVs) recently emerged as novel diagnostic and prognostic biomarkers in patients with liver cancer, but no data on its prognostic relevance in the context of TACE exists. Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.
Vesicle size distribution and concentration were measured by nanoparticle tracking analysis (NTA) in patient sera before and after TACE in 38 patients.
Extracellular vesicle size distribution measured before TACE is of prognostic significance with respect to overall survival in patients after TACE. Overall survival is significantly reduced when initial vesicle size (X50) is in the upper quartile (>145.65nm). Median overall survival in patients in the upper quartile was only 314 days, compared to 799 days in patients with vesicle size in the first to third quartile ( |
| doi_str_mv | 10.1371/journal.pone.0255983 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2562504582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A672477514</galeid><doaj_id>oai_doaj_org_article_8c4843cce9714296a2bfccf1306260d3</doaj_id><sourcerecordid>A672477514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-dda8c609d9f26829b1ef7207fd5abc3816b3e930c5ec710e77cb01410a7dcf063</originalsourceid><addsrcrecordid>eNqNk9-L1DAQx4so3nn6H4gGBNGHXfOjTdoXYVlWXTg40NPXkE2m3RzdZC9pF_0v_JNN3d6xlXuQPmQ685lvMzOdLHtJ8JwwQT7c-D441c733sEc06KoSvYoOycVozNOMXt8Yp9lz2K8wbhgJedPszOW51jgCp9nv1euVaEBg-BnF5SGtu2TAx0gWt1CRCoAUshBozp7ALQPvnE-dlajWunOB2Qd2qcYuC6i3hkIjbeuQdeL5QrVKb4PdqfCL5TMCNo7M7y0SSsgrZyGMFPJiJCiwUJ8nj2pVRvhxXheZN8_ra6XX2aXV5_Xy8XlTPOKdjNjVKk5rkxVU17SakOgFhSL2hRqo1lJ-IZBxbAuQAuCQQi9wSQnWAmja8zZRfb6qLtvfZRjM6OkBacFzouSJmJ9JIxXN3IsQ3pl5V-HD41UoRu6JEudlznTGipBclpxRTe11jVhmFOODUtaH8ev9ZsdGJ26FVQ7EZ1GnN3Kxh9kyQStWJEE3o0Cwd_2EDu5s3GYlnLg--O9S0ZKkSf0zT_ow9WNVKNSAdbVfhj_ICoXXNBciIIMWvMHqPQY2Nk0TKht8k8S3k8SEtOlP6tRfYxy_e3r_7NXP6bs2xN2C6rtttG3fWe9i1MwP4I6-BgD1PdNJlgOi3PXDTksjhwXJ6W9Oh3QfdLdprA_VV8VTQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562504582</pqid></control><display><type>article</type><title>Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Schöler, David ; Castoldi, Mirco ; Jördens, Markus S ; Schulze-Hagen, Max ; Kuhl, Christiane ; Keitel, Verena ; Luedde, Tom ; Roderburg, Christoph ; Loosen, Sven H</creator><contributor>Avila, Matias A.</contributor><creatorcontrib>Schöler, David ; Castoldi, Mirco ; Jördens, Markus S ; Schulze-Hagen, Max ; Kuhl, Christiane ; Keitel, Verena ; Luedde, Tom ; Roderburg, Christoph ; Loosen, Sven H ; Avila, Matias A.</creatorcontrib><description>Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concentration and sizes of extracellular vesicles (EVs) recently emerged as novel diagnostic and prognostic biomarkers in patients with liver cancer, but no data on its prognostic relevance in the context of TACE exists. Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.
Vesicle size distribution and concentration were measured by nanoparticle tracking analysis (NTA) in patient sera before and after TACE in 38 patients.
Extracellular vesicle size distribution measured before TACE is of prognostic significance with respect to overall survival in patients after TACE. Overall survival is significantly reduced when initial vesicle size (X50) is in the upper quartile (>145.65nm). Median overall survival in patients in the upper quartile was only 314 days, compared to 799 days in patients with vesicle size in the first to third quartile (<145.65nm; p = 0.007). Vesicle size was also shown to be a significant prognostic marker for overall survival in Cox regression analysis [HR 1.089, 95% CI: 1.021-1.162, p = 0.010]. In addition, a significant correlation was observed between initial EVs concentration/BMI (rS = 0.358, p = 0.029), X50/IL-8-concentration (rS = 0.409, p = 0.011) and X50/CRP-concentration (rS = 0.404, p = 0.016). In contrast, with regard to immediate tumor response after TACE, EVs concentration and size did not differ.
Sizes (but not concentrations) of EVs represent a novel prognostic marker in patients receiving TACE for primary and secondary hepatic malignancies since patients with enlarged EVs display a significantly impaired prognosis after TACE.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0255983</identifier><identifier>PMID: 34407090</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biological markers ; Biology and Life Sciences ; Biomarkers ; Biomarkers, Tumor - blood ; Chemoembolization, Therapeutic - methods ; Evaluation ; Extracellular vesicles ; Extracellular Vesicles - metabolism ; Extracellular Vesicles - pathology ; Female ; Gastroenterology ; Hepatology ; Hospitals ; Humans ; Infectious diseases ; Interleukin 8 ; Liver ; Liver cancer ; Liver cirrhosis ; Liver Neoplasms - blood ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Liver Neoplasms - pathology ; Male ; Medical prognosis ; Medicine and Health Sciences ; Metastases ; Metastasis ; Middle Aged ; Nanoparticles ; Neoplasm Metastasis ; Particle Size ; Patients ; Prognosis ; Regression analysis ; Size distribution ; Software ; Supervision ; Survival ; Survival Rate ; Treatment Outcome ; Tumors ; Vesicles</subject><ispartof>PloS one, 2021-08, Vol.16 (8), p.e0255983-e0255983</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Schöler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Schöler et al 2021 Schöler et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-dda8c609d9f26829b1ef7207fd5abc3816b3e930c5ec710e77cb01410a7dcf063</citedby><cites>FETCH-LOGICAL-c692t-dda8c609d9f26829b1ef7207fd5abc3816b3e930c5ec710e77cb01410a7dcf063</cites><orcidid>0000-0002-2736-9778</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372935/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372935/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34407090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Avila, Matias A.</contributor><creatorcontrib>Schöler, David</creatorcontrib><creatorcontrib>Castoldi, Mirco</creatorcontrib><creatorcontrib>Jördens, Markus S</creatorcontrib><creatorcontrib>Schulze-Hagen, Max</creatorcontrib><creatorcontrib>Kuhl, Christiane</creatorcontrib><creatorcontrib>Keitel, Verena</creatorcontrib><creatorcontrib>Luedde, Tom</creatorcontrib><creatorcontrib>Roderburg, Christoph</creatorcontrib><creatorcontrib>Loosen, Sven H</creatorcontrib><title>Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concentration and sizes of extracellular vesicles (EVs) recently emerged as novel diagnostic and prognostic biomarkers in patients with liver cancer, but no data on its prognostic relevance in the context of TACE exists. Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.
Vesicle size distribution and concentration were measured by nanoparticle tracking analysis (NTA) in patient sera before and after TACE in 38 patients.
Extracellular vesicle size distribution measured before TACE is of prognostic significance with respect to overall survival in patients after TACE. Overall survival is significantly reduced when initial vesicle size (X50) is in the upper quartile (>145.65nm). Median overall survival in patients in the upper quartile was only 314 days, compared to 799 days in patients with vesicle size in the first to third quartile (<145.65nm; p = 0.007). Vesicle size was also shown to be a significant prognostic marker for overall survival in Cox regression analysis [HR 1.089, 95% CI: 1.021-1.162, p = 0.010]. In addition, a significant correlation was observed between initial EVs concentration/BMI (rS = 0.358, p = 0.029), X50/IL-8-concentration (rS = 0.409, p = 0.011) and X50/CRP-concentration (rS = 0.404, p = 0.016). In contrast, with regard to immediate tumor response after TACE, EVs concentration and size did not differ.
Sizes (but not concentrations) of EVs represent a novel prognostic marker in patients receiving TACE for primary and secondary hepatic malignancies since patients with enlarged EVs display a significantly impaired prognosis after TACE.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biological markers</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Evaluation</subject><subject>Extracellular vesicles</subject><subject>Extracellular Vesicles - metabolism</subject><subject>Extracellular Vesicles - pathology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interleukin 8</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine and Health Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Nanoparticles</subject><subject>Neoplasm Metastasis</subject><subject>Particle Size</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Size distribution</subject><subject>Software</subject><subject>Supervision</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vesicles</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-L1DAQx4so3nn6H4gGBNGHXfOjTdoXYVlWXTg40NPXkE2m3RzdZC9pF_0v_JNN3d6xlXuQPmQ685lvMzOdLHtJ8JwwQT7c-D441c733sEc06KoSvYoOycVozNOMXt8Yp9lz2K8wbhgJedPszOW51jgCp9nv1euVaEBg-BnF5SGtu2TAx0gWt1CRCoAUshBozp7ALQPvnE-dlajWunOB2Qd2qcYuC6i3hkIjbeuQdeL5QrVKb4PdqfCL5TMCNo7M7y0SSsgrZyGMFPJiJCiwUJ8nj2pVRvhxXheZN8_ra6XX2aXV5_Xy8XlTPOKdjNjVKk5rkxVU17SakOgFhSL2hRqo1lJ-IZBxbAuQAuCQQi9wSQnWAmja8zZRfb6qLtvfZRjM6OkBacFzouSJmJ9JIxXN3IsQ3pl5V-HD41UoRu6JEudlznTGipBclpxRTe11jVhmFOODUtaH8ev9ZsdGJ26FVQ7EZ1GnN3Kxh9kyQStWJEE3o0Cwd_2EDu5s3GYlnLg--O9S0ZKkSf0zT_ow9WNVKNSAdbVfhj_ICoXXNBciIIMWvMHqPQY2Nk0TKht8k8S3k8SEtOlP6tRfYxy_e3r_7NXP6bs2xN2C6rtttG3fWe9i1MwP4I6-BgD1PdNJlgOi3PXDTksjhwXJ6W9Oh3QfdLdprA_VV8VTQ</recordid><startdate>20210818</startdate><enddate>20210818</enddate><creator>Schöler, David</creator><creator>Castoldi, Mirco</creator><creator>Jördens, Markus S</creator><creator>Schulze-Hagen, Max</creator><creator>Kuhl, Christiane</creator><creator>Keitel, Verena</creator><creator>Luedde, Tom</creator><creator>Roderburg, Christoph</creator><creator>Loosen, Sven H</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2736-9778</orcidid></search><sort><creationdate>20210818</creationdate><title>Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series</title><author>Schöler, David ; Castoldi, Mirco ; Jördens, Markus S ; Schulze-Hagen, Max ; Kuhl, Christiane ; Keitel, Verena ; Luedde, Tom ; Roderburg, Christoph ; Loosen, Sven H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-dda8c609d9f26829b1ef7207fd5abc3816b3e930c5ec710e77cb01410a7dcf063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biological markers</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Evaluation</topic><topic>Extracellular vesicles</topic><topic>Extracellular Vesicles - metabolism</topic><topic>Extracellular Vesicles - pathology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interleukin 8</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine and Health Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Nanoparticles</topic><topic>Neoplasm Metastasis</topic><topic>Particle Size</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Size distribution</topic><topic>Software</topic><topic>Supervision</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vesicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schöler, David</creatorcontrib><creatorcontrib>Castoldi, Mirco</creatorcontrib><creatorcontrib>Jördens, Markus S</creatorcontrib><creatorcontrib>Schulze-Hagen, Max</creatorcontrib><creatorcontrib>Kuhl, Christiane</creatorcontrib><creatorcontrib>Keitel, Verena</creatorcontrib><creatorcontrib>Luedde, Tom</creatorcontrib><creatorcontrib>Roderburg, Christoph</creatorcontrib><creatorcontrib>Loosen, Sven H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schöler, David</au><au>Castoldi, Mirco</au><au>Jördens, Markus S</au><au>Schulze-Hagen, Max</au><au>Kuhl, Christiane</au><au>Keitel, Verena</au><au>Luedde, Tom</au><au>Roderburg, Christoph</au><au>Loosen, Sven H</au><au>Avila, Matias A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-08-18</date><risdate>2021</risdate><volume>16</volume><issue>8</issue><spage>e0255983</spage><epage>e0255983</epage><pages>e0255983-e0255983</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concentration and sizes of extracellular vesicles (EVs) recently emerged as novel diagnostic and prognostic biomarkers in patients with liver cancer, but no data on its prognostic relevance in the context of TACE exists. Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies.
Vesicle size distribution and concentration were measured by nanoparticle tracking analysis (NTA) in patient sera before and after TACE in 38 patients.
Extracellular vesicle size distribution measured before TACE is of prognostic significance with respect to overall survival in patients after TACE. Overall survival is significantly reduced when initial vesicle size (X50) is in the upper quartile (>145.65nm). Median overall survival in patients in the upper quartile was only 314 days, compared to 799 days in patients with vesicle size in the first to third quartile (<145.65nm; p = 0.007). Vesicle size was also shown to be a significant prognostic marker for overall survival in Cox regression analysis [HR 1.089, 95% CI: 1.021-1.162, p = 0.010]. In addition, a significant correlation was observed between initial EVs concentration/BMI (rS = 0.358, p = 0.029), X50/IL-8-concentration (rS = 0.409, p = 0.011) and X50/CRP-concentration (rS = 0.404, p = 0.016). In contrast, with regard to immediate tumor response after TACE, EVs concentration and size did not differ.
Sizes (but not concentrations) of EVs represent a novel prognostic marker in patients receiving TACE for primary and secondary hepatic malignancies since patients with enlarged EVs display a significantly impaired prognosis after TACE.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34407090</pmid><doi>10.1371/journal.pone.0255983</doi><tpages>e0255983</tpages><orcidid>https://orcid.org/0000-0002-2736-9778</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-08, Vol.16 (8), p.e0255983-e0255983 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2562504582 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adult Aged Aged, 80 and over Analysis Biological markers Biology and Life Sciences Biomarkers Biomarkers, Tumor - blood Chemoembolization, Therapeutic - methods Evaluation Extracellular vesicles Extracellular Vesicles - metabolism Extracellular Vesicles - pathology Female Gastroenterology Hepatology Hospitals Humans Infectious diseases Interleukin 8 Liver Liver cancer Liver cirrhosis Liver Neoplasms - blood Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - pathology Male Medical prognosis Medicine and Health Sciences Metastases Metastasis Middle Aged Nanoparticles Neoplasm Metastasis Particle Size Patients Prognosis Regression analysis Size distribution Software Supervision Survival Survival Rate Treatment Outcome Tumors Vesicles |
| title | Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A18%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enlarged%20extracellular%20vesicles%20are%20a%20negative%20prognostic%20factor%20in%20patients%20undergoing%20TACE%20for%20primary%20or%20secondary%20liver%20cancer-a%20case%20series&rft.jtitle=PloS%20one&rft.au=Sch%C3%B6ler,%20David&rft.date=2021-08-18&rft.volume=16&rft.issue=8&rft.spage=e0255983&rft.epage=e0255983&rft.pages=e0255983-e0255983&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0255983&rft_dat=%3Cgale_plos_%3EA672477514%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2562504582&rft_id=info:pmid/34407090&rft_galeid=A672477514&rft_doaj_id=oai_doaj_org_article_8c4843cce9714296a2bfccf1306260d3&rfr_iscdi=true |